This is a regulatory intimation submitted to BSE Limited and the National Stock Exchange of India Limited regarding a scheduled meeting of the Board of Directors of Eris Lifesciences Limited.
The Board Meeting is scheduled for Monday, October 26, 2026. The primary purpose of the meeting is to consider and approve the company's standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026.
The company had previously informed the exchanges via a letter dated September 28, 2026, that the trading window for dealing in the company's securities was closed for designated persons. The closure became effective from October 01, 2026. The trading window will remain closed until 48 hours after the financial results are declared to the public. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons'.
The notice was issued by Milind Talegaonkar, Company Secretary & Compliance Officer (ICSI Membership No: A26493), on behalf of Eris Lifesciences Limited.